Latest Intelligence on Vaccines in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Vaccines have re-emerged as growth drivers for the biopharmaceutical industry

Prior to 2000, vaccines were generally regarded as a commodity market with limited revenue opportunities. However, advances in vaccine technology, the launch of new vaccines, increased investment in research, a change of public opinion about vaccination, and more favorable legislation regarding vaccine injury compensation have contributed to their re-emergence as successful growth drivers.

Published By Datamonitor
01 Dec 2010
CommentWire
CommentWire

Vaccines: further consolidation through Sanofi cash bid for Acambis

Sanofi Pasteur's offer, valuing Acambis at GBP276m, will give the French pharmaceutical firm extended access to Acambis's large vaccine pipeline, particularly to a universal influenza vaccine candidate and a Clostridium difficile vaccine. The acquisition represents a further important consolidation step in the growing vaccines market, leaving Austria's Intercell as the next big takeover target.

Published By Datamonitor
29 Jul 2008
CommentWire
CommentWire

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.